Stock comparison
McKesson
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MCK
McKesson
Market cap
$91.42B
Sector
Healthcare
RMD
ResMed
Market cap
$29.57B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MCK | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 57C | 64C | RMD |
| Benjamin Graham | 28F | 67B | RMD |
| Philip Fisher |
Side-by-side metrics
| Metric | MCK | RMD |
|---|---|---|
| Market cap | $91.42B | $29.57B |
| P/E (TTM) | 19.5x | 19.6x |
| EV/EBIT | 14.9x | 17.1x |
| ROIC (TTM) | 31.07% | 19.63% |
| Gross margin | 3.61% | 61.69% |
| Net margin | 1.18% | 27.44% |
| Revenue CAGR 5y | 11.19% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MCK leads on
- Debt / Equity-vs 0.1x+103%
- Market cap$91.42Bvs $29.57B+68%
- EPS CAGR 5y51.54%vs 30.73%+40%
- ROIC (TTM)31.07%vs 19.63%
More like RMD
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.